What Charity Do I Support

Published on 22 November 2025 at 13:28

As an artist with Crohn's Bowel Disease in New Zealand, I like to support the Crohn's and Colitis New Zealand Foundation.

Inflammatory Bowel Disease is a term used for chronic inflammatory conditions of the intestines, most commonly Crohn's Disease and Ulcerative Colitis.

The two primary forms are Crohn's disease and ulcerative colitis.

  • Ulcerative colitis: Affects the large intestine (colon).
  • Crohn's disease: Can affect any part of the gastrointestinal tract, from the mouth to the anus. 

 

It results from an abnormal immune response that causes inflammation, leading to symptoms like abdominal pain, diarrhoea, and rectal bleeding. It is a chronic condition, meaning the inflammation is long-lasting and can lead to permanent damage.

 

The symptoms can range from diarrhoea to abdominal pain. Rectal bleeding, Urgency to have a bowel movement, fatigue  and arthritis

 

The current estimate of people in New Zealand who have IBD is 20,000; however, this is expected to double to over 40,000 by 2045, which is in 20 years.

Globally, we have one of the highest rates of IBD in the world, and we also have the highest rate of bowel cancer and bowel issues globally.

However, the data limitations are that the exact, up-to-date prevalence is difficult to determine because there is no national IBD registry in New Zealand.

 

IBD is distinct from Irritable Bowel Syndrome (IBS), which does not involve inflammation or permanent bowel damage. 

 

  • IBD: Involves inflammation and can cause permanent damage to the bowel.
  • IBS: Does not involve inflammation and does not result in permanent bowel damage. 

 

 

All paintings, no matter when they are brought, $50 from each painting goes towards this cause.

You can check my paintings out here.

If you want to help, please buy a painting, or you can go directly to their site to see how you can show your support here: https://crohnsandcolitis.org.nz/support%20%26%20information

Add comment

Comments

There are no comments yet.